U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H25NO3
Molecular Weight 351.4388
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAMIBAROTENE

SMILES

CC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C3=CC=C(C=C3)C(O)=O)=C2

InChI

InChIKey=MUTNCGKQJGXKEM-UHFFFAOYSA-N
InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/amnolake.html | https://www.ncbi.nlm.nih.gov/pubmed/20925433 | https://www.ncbi.nlm.nih.gov/pubmed/20925433 | https://www.ncbi.nlm.nih.gov/pubmed/24559497 | https://www.ncbi.nlm.nih.gov/pubmed/27777437

Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, the synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukemia (APL). Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta. It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. It has also been investigated as a possible treatment for Alzheimer's disease, multiple myeloma, and Crohn's disease.

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 45.0 nM [EC50]
Agonist
2752
 235.0 nM [EC50]
Agonist
2752
 591.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Amnolake

Approved Use

Unknown
Primary
Phase II
1147
Amnolake

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.02 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
44.87 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
65.22 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
63.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
6 mg/m² single, oral
dose: 6 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
104.4 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
8 mg/m² single, oral
dose: 8 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
126.3 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
10 mg/m² single, oral
dose: 10 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
131.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
12 mg/m² single, oral
dose: 12 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
43.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
97.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
128.37 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
320.41 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
430.26 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
311.1 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
6 mg/m² single, oral
dose: 6 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
438.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
8 mg/m² single, oral
dose: 8 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
444.2 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
10 mg/m² single, oral
dose: 10 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
514.1 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
12 mg/m² single, oral
dose: 12 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
312 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
751 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.4 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.5 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/480114_4291014F1021_1_A04_1F.pdf#page=13 | https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/480114_4291014F1021_1_12#page=4
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
11.96 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
6 mg/m² single, oral
dose: 6 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
2.35 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
8 mg/m² single, oral
dose: 8 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
2.49 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
10 mg/m² single, oral
dose: 10 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
2.21 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33829292/
12 mg/m² single, oral
dose: 12 mg/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
3.38 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.38 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26202410/
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAMIBAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.6%
OTHER GOV'T
https://www.pmda.go.jp/drugs/2005/P200500012/48011400_21700AMZ00596_Q100_2.pdf#page=30 | https://www.pmda.go.jp/drugs/2005/P200500012/48011400_21700AMZ00596_W101_1.pdf#page=1 | https://pubmed.ncbi.nlm.nih.gov/9105544/
TAMIBAROTENE plasma
Homo sapiens
population:
age:
sex: MALE
food status:
Doses

Doses

DosePopulationAdverse events​
6 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 6 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21820159/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21820159/
Disc. AE: abnormal coagulation...
AEs leading to
discontinuation/dose reduction:
abnormal coagulation
Sources:
https://pubmed.ncbi.nlm.nih.gov/21820159/
12 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 12 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33829292/
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33829292/
Other AEs: hyperglyceridemi...
Other AEs:
hyperglyceridemi
Sources:
https://pubmed.ncbi.nlm.nih.gov/33829292/
AEs

AEs

AESignificanceDosePopulation
abnormal coagulation Disc. AE
6 mg/m2 1 times / day multiple, oral
Studied dose
Dose: 6 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21820159/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21820159/
hyperglyceridemi
12 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 12 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33829292/
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33829292/
PubMed

PubMed

TitleDatePubMed
Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.
2012-01-05
All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
2011-08
Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
2011-03-01
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
2010-10-14
Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
2010-10
Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.
2010-06-24
Disturbance of rapid eye movement sleep in senescence-accelerated mouse prone/8 mice is improved by retinoic acid receptor agonist Am80 (Tamibarotene).
2010-05-19
[Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].
2010-04
Am80 inhibits stromal cell-derived factor-1-induced chemotaxis in T-cell acute lymphoblastic leukemia cells.
2010-03
Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.
2010-01-26
Disposition of a new tamibarotene prodrug in mice.
2009-12
The ATRA-dependent overexpression of the glutamate transporter EAAC1 requires RARbeta induction.
2009-09
Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis.
2009-07-01
Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling.
2009-07
Chemopreventive effect of 4-[3,5-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) on MNU-induced colon carcinogenesis in a rat model.
2009-06
Towards retinoid therapy for Alzheimer's disease.
2009-06
Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells.
2009-06
The effect of Am-80, a synthetic retinoid, on spinal cord injury-induced motor dysfunction in rats.
2009-02
Tamibarotene.
2007-08
RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells.
2007-08
4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
2007-04-18
All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling.
2007-03
Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid.
2007-01
Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes.
2006-09-15
[Retinoid therapy for autoimmune diseases].
2006-06
Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6.
2006-05
[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
2006-03
Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells.
2005-12-30
Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5.
2005-11-25
Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis.
2005-06
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
2005-03-31
Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis.
2004-12-01
A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
2004-09
Promyelocytic leukemia retinoid signaling targets regulate apoptosis,tissue factor and thrombomodulin expression.
2004-03
Tamibarotene: AM 80, retinobenzoic acid, Tamibaro.
2004
Inhibition by retinoids of antigen-induced IL-4 production in rat mast cell line RBL-2H3.
2001-02-02
On-line immunoaffinity extraction followed by high-performance liquid chromatography and radioimmunoassay for a novel retinobenzoic acid, AM-80, in human plasma.
2001
Thyroid hormone regulation of apoptosis induced by retinoic acid in promyeloleukemic HL-60 cells: studies with retinoic acid receptor-specific and retinoid x receptor-specific ligands.
2000-12
Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid.
2000-12
Effect of selective IL-6 inhibitor Am-80 on experimental autoimmune encephalomyelitis in DA rats.
2000-11
The effect of Am-80, one of retinoids derivatives on experimental allergic encephalomyelitis in rats.
2000-09-01
Effect of Am-80, a retinoid derivative, on 2, 4-dinitrofluorobenzene-induced contact dermatitis in mice.
2000-05
Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation.
2000-04-03
Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice.
1999-02
Action mechanism of retinoid-synergistic dibenzodiazepines.
1997-04-07
Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
1997-04
Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
1997-03
Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
1995-07
The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha.
1994
Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.
1988-11
Patents

Patents

WO1991014673
1

Sample Use Guides

In Vivo Use Guide
Tamibarotene 6 mg/m2/day oral dose for a maximum of 56 days
Route of Administration: Oral
In Vitro Use Guide
The cell viability of A549 or MRC-5 cell lines treated with Am80 or ATRA was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega KK, Tokyo, Japan). Cells were seeded at 625 per cm2 in 100 μL of medium in 96-welled flat-bottom plates and grown overnight at 37°C in an incubator. After exposure to Am80 for 6 d, the plates were assayed using EnVision Plate Reader (PerkinElmer, Inc. Japan Co., Ltd., Kanagawa, Japan).
Name Type Language
AM-80
Preferred Name English
TAMIBAROTENE
INN   JAN   MART.   MI   WHO-DD  
USAN   INN  
Official Name English
AM80
Code English
TAMIBAROTENE [JAN]
Common Name English
RR-110
Code English
OP-01
Code English
SY-1425
Code English
4-(((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)AMINO)CARBONYL)BENZOIC ACID
Systematic Name English
BENZOIC ACID, 4-(((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)AMINO)CARBONYL)-
Systematic Name English
TM-411
Code English
TAMIBAROTENE [USAN]
Common Name English
4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)CARBAMOYL)BENZOIC ACID
Systematic Name English
NSC-608000
Code English
tamibarotene [INN]
Common Name English
INNO-507
Code English
Tamibarotene [WHO-DD]
Common Name English
TOS-80T
Code English
AMNOID
Brand Name English
TAMIBAROTENE [MI]
Common Name English
TAMIBAROTENE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C804
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
FDA ORPHAN DRUG 247007
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
FDA ORPHAN DRUG 596017
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
EU-Orphan Drug EU/3/09/658
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
FDA ORPHAN DRUG 861221
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
Code System Code Type Description
CHEBI
32181
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
IUPHAR
2648
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
NSC
608000
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
NCI_THESAURUS
C71025
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
USAN
JK-51
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
MERCK INDEX
m10449
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID5046853
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
EVMPD
SUB10822MIG
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
FDA UNII
08V52GZ3H9
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
PUBCHEM
108143
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
SMS_ID
100000083232
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
ChEMBL
CHEMBL25202
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
CAS
94497-51-5
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
DRUG CENTRAL
3580
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
DRUG BANK
DB04942
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
INN
7349
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
MESH
C061133
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
WIKIPEDIA
TAMIBAROTENE
Created by admin on Mon Mar 31 18:32:02 GMT 2025 , Edited by admin on Mon Mar 31 18:32:02 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of TAMIBAROTENE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966